Media-OutReach Newswire AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance
Media-OutReach Newswire The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration
Media-OutReach Newswire AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
Media-OutReach Newswire Phase III clinical data of AIM Vaccine iterative serum-free rabies vaccine reaches preset goals
Media-OutReach Newswire The bull market of innovative drug technology is booming, and the leading stock AIM Vaccine has erupted upward
Media-OutReach Newswire AIM Vaccine submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine
Media-OutReach Newswire YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP